AR120038A1 - Anticuerpos anti-nrp1a y sus usos para tratar enfermedades oculares - Google Patents

Anticuerpos anti-nrp1a y sus usos para tratar enfermedades oculares

Info

Publication number
AR120038A1
AR120038A1 ARP200102648A ARP200102648A AR120038A1 AR 120038 A1 AR120038 A1 AR 120038A1 AR P200102648 A ARP200102648 A AR P200102648A AR P200102648 A ARP200102648 A AR P200102648A AR 120038 A1 AR120038 A1 AR 120038A1
Authority
AR
Argentina
Prior art keywords
nrp1a
antibodies
eye diseases
treat eye
treat
Prior art date
Application number
ARP200102648A
Other languages
English (en)
Inventor
Nina Zippel
Pankaj Gupta
Fei Han
Yining Huang
Sarah Low
Juergen Prestle
Leo Thomas
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of AR120038A1 publication Critical patent/AR120038A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Anticuerpos y fragmentos de estos que actúan sobre el domino A de Neuropilina-1 (Nrp1A). Más específicamente, anticuerpos anti-Nrp1A y métodos de uso para el tratamiento de varias enfermedades o trastornos.
ARP200102648A 2019-09-24 2020-09-23 Anticuerpos anti-nrp1a y sus usos para tratar enfermedades oculares AR120038A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP19199099 2019-09-24

Publications (1)

Publication Number Publication Date
AR120038A1 true AR120038A1 (es) 2022-01-26

Family

ID=68066567

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP200102648A AR120038A1 (es) 2019-09-24 2020-09-23 Anticuerpos anti-nrp1a y sus usos para tratar enfermedades oculares

Country Status (2)

Country Link
AR (1) AR120038A1 (es)
EC (1) ECSP22020678A (es)

Also Published As

Publication number Publication date
ECSP22020678A (es) 2022-04-29

Similar Documents

Publication Publication Date Title
CL2019001874A1 (es) Inhibidores de tgfß1 isoforma-específicos contexto-permisivos y uso de los mismos.
CL2019003636A1 (es) Polinucleótidos de aadc para el tratamiento de la enfermedad de parkinson.
ES2692773T3 (es) Tratamientos para la fibrosis
CL2017000285A1 (es) Terapia combinada para el tratamiento de un paramixovirus
PE20210488A1 (es) Anticuerpos especificos para gucy2c y sus usos
CL2019000935A1 (es) Composición farmacéutica, métodos para tratamiento y usos de la misma.
CO2021014768A2 (es) Anticuerpos anti-sema3a y sus usos para tratar enfermedades oculares
CO2018005393A2 (es) Anticuerpos anti-htra1 y métodos de uso de los mismos
AR115583A1 (es) Composiciones y métodos para el tratamiento de las enfermedades y trastornos del hígado
CO2020014510A2 (es) Estimulador de treg selectivo rur20kd-il-2 y composiciones relacionadas
CO2021004141A2 (es) Moduladores de la expresión de pnpla3
CL2019001749A1 (es) Uso de anticuerpos anti-esclerostina en el tratamiento de osteogenesis imperfecta.
CL2019002574A1 (es) Moduladores de la expresión de pcsk9.
AR113618A1 (es) Péptidos antimicrobianos y métodos para usarlos
CL2021000930A1 (es) Piridazinas novedosas
CO2021007006A2 (es) Moduladores de la expresión de irf5
MX2022006073A (es) Metodos para utilizar anticuerpos anti-trem2.
BR112021017550A2 (pt) Métodos de tratamento da amiloidose al
CL2021002866A1 (es) Tratamiento de la cefalea usando anticuerpos anti-cgrp.
EA202090266A1 (ru) Ингибиторы mpo для применения в медицине
UY38472A (es) Moduladores de la expresión de foxp3
BR112018012126A2 (pt) ?adjuvante, método para prevenir e/ou tratar uma doença autoimune, e, uso de um adjuvante?
EA202191058A1 (ru) Антитела против муцина-16 и способы их применения
AR120038A1 (es) Anticuerpos anti-nrp1a y sus usos para tratar enfermedades oculares
CO2022003324A2 (es) Anticuerpos anti-nrp1a y sus usos para tratar enfermedades oculares